HOME >> MEDICINE >> NEWS
Jefferson researchers find drug may give some cardiac protection 24 hours after heart attack

A drug has been shown to provide some protection to the heart from injury even if given as much as 24 hours after a heart attack, Jefferson Medical College researchers report. Walter Koch, Ph.D., director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, and his co-workers knew that the drug Darbepoietin alpha would protect the ischemic heart. Darbepoietin is a long-acting cousin of erythropoietin (EPO), which has been shown to offer some protection to the heart from injury from ischemia, or a lack of oxygen. In previous studies, Dr. Koch had given EPO at the time of simulated heart attack in an another animal model, and found it protected the animals.

But in further studies, Dr. Koch gave Darbepoietin to animals at the time of ischemia and heart attack, one to two hours after, and 24 hours later. In each case, the scientists saw that the drug offered significant protection to heart tissue, and even helped improve cardiac function. Dr. Koch believes the results "may be quickly translated into clinical trials." He and his team present their findings on November 16, 2005 at the American Heart Association's Scientific Sessions 2005 in Dallas.


'"/>


16-Nov-2005


Page: 1

Related medicine news :

1. Fat protein cuts blood vessel inflammation, may help heart, Jefferson scientists find
2. Jefferson pharmacologist says biomarker discovery bodes well for better cancer diagnostics
3. Jefferson immunology researchers show blood-brain barrier damage could affect MS severity
4. Jefferson scientists find that plavix appears to be safe during and after heart bypass
5. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
6. Jefferson scientists find that drug-eluting stents are disappointing in bypass grafts -- sometimes
7. Empathy skills must be given a high priority in medical education, says Jefferson author
8. Natural, soy-based substance might help fight MS, Jefferson neuroscientists find
9. Blood pressure drugs could help halt pancreatic cancer spread, Jefferson researchers find
10. Obesity tied to higher risk of complications in spinal surgery, Jefferson neurosurgeon finds
11. Jefferson Orthopaedic surgeons leading international study of timing of spinal surgery

Post Your Comments:
(Date:5/18/2013)... In a May 14, 2013 article entitled “Angelina Jolie ... Gene,” Fox News reported the movie star had opted ... a gene that doctors estimated gave her an 87 ... risk of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s ... a blog post entitled “A Patient’s Journey: Angelina Jolie” ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... 2013 TheBeautyPlace.com answers important questions about ... is not a result of stress, nutrient deficiency or ... Magazine, 70% of men suffer from male patterned baldness. ... renowned for hair transplant surgery, but additionally carries a ... known as Bosley Professional Strength. Their product line is ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
Cached News: